$3.25
-0.09[-2.69%]
At close: Apr 19
$3.25
0[0.00%]
After Hours: 4:57PM EDT
Mersana Therapeutics
(NASDAQ:MRSN)Mersana Therapeutics Stock (NASDAQ:MRSN), Analyst Ratings, Price Targets, Predictions
Mersana Therapeutics Inc has a consensus price target of $9, established from looking at the 21 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, Wedbush, and Truist Securities on March 19, 2024, February 29, 2024, and February 29, 2024. With an average price target of $7 between JP Morgan, Wedbush, and Truist Securities, there's an implied 115.38% upside for Mersana Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
Wedbush
Truist Securities
Baird
Guggenheim
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Mersana Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/19/2024 | MRSN | Buy Now | Mersana Therapeutics | $3.25 | 53.85% | JP Morgan | Brian Cheng | → $5 | Upgrade | Underweight → Neutral | Get Alert |
| 02/29/2024 | MRSN | Buy Now | Mersana Therapeutics | $3.25 | 115.38% | Wedbush | David Nierengarten | $2 → $7 | Upgrade | Neutral → Outperform | Get Alert |
| 02/29/2024 | MRSN | Buy Now | Mersana Therapeutics | $3.25 | 176.92% | Truist Securities | Asthika Goonewardene | $9 → $9 | Upgrade | Hold → Buy | Get Alert |
| 02/29/2024 | MRSN | Buy Now | Mersana Therapeutics | $3.25 | 53.85% | Baird | Colleen Kusy | $1 → $5 | Maintains | Neutral | Get Alert |
| 02/29/2024 | MRSN | Buy Now | Mersana Therapeutics | $3.25 | 115.38% | Guggenheim | Michael Schmidt | → $7 | Upgrade | Neutral → Buy | Get Alert |
| 12/04/2023 | MRSN | Buy Now | Mersana Therapeutics | $3.25 | 53.85% | Citigroup | Ashiq Mubarack | $1 → $5 | Upgrade | Neutral → Buy | Get Alert |
| 07/28/2023 | MRSN | Buy Now | Mersana Therapeutics | $3.25 | -69.23% | Citigroup | Ashik Kurian | $10 → $1 | Downgrade | Buy → Neutral | Get Alert |
| 07/28/2023 | MRSN | Buy Now | Mersana Therapeutics | $3.25 | -69.23% | Baird | Colleen Kusy | $7 → $1 | Downgrade | Outperform → Neutral | Get Alert |
| 07/27/2023 | MRSN | Buy Now | Mersana Therapeutics | $3.25 | -38.46% | Wedbush | David Nierengarten | $12 → $2 | Downgrade | Outperform → Neutral | Get Alert |
| 07/27/2023 | MRSN | Buy Now | Mersana Therapeutics | $3.25 | — | Truist Securities | Asthika Goonewardene | — | Downgrade | Buy → Hold | Get Alert |
| 06/16/2023 | MRSN | Buy Now | Mersana Therapeutics | $3.25 | 207.69% | Citigroup | Ashik Kurian | $15 → $10 | Maintains | Buy | Get Alert |
| 06/16/2023 | MRSN | Buy Now | Mersana Therapeutics | $3.25 | 53.85% | JP Morgan | Brian Cheng | $11 → $5 | Downgrade | Overweight → Neutral | Get Alert |
| 06/15/2023 | MRSN | Buy Now | Mersana Therapeutics | $3.25 | 330.77% | Guggenheim | Michael Schmidt | → $14 | Initiates | → Buy | Get Alert |
| 05/11/2023 | MRSN | Buy Now | Mersana Therapeutics | $3.25 | 361.54% | Citigroup | Ashik Kurian | $12 → $15 | Maintains | Buy | Get Alert |
| 03/16/2023 | MRSN | Buy Now | Mersana Therapeutics | $3.25 | 207.69% | JP Morgan | Brian Cheng | → $10 | Upgrade | Neutral → Overweight | Get Alert |
| 11/21/2022 | MRSN | Buy Now | Mersana Therapeutics | $3.25 | 269.23% | Truist Securities | Asthika Goonewardene | → $12 | Initiates | → Buy | Get Alert |
| 08/09/2022 | MRSN | Buy Now | Mersana Therapeutics | $3.25 | 515.38% | Baird | Colleen Kusy | $18 → $20 | Maintains | Outperform | Get Alert |
| 08/09/2022 | MRSN | Buy Now | Mersana Therapeutics | $3.25 | 330.77% | SVB Leerink | Jonathan Chang | $13 → $14 | Maintains | Outperform | Get Alert |
| 05/09/2022 | MRSN | Buy Now | Mersana Therapeutics | $3.25 | 330.77% | SVB Leerink | Jonathan Chang | $13 → $14 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Mersana Therapeutics (MRSN)?
The latest price target for Mersana Therapeutics (NASDAQ: MRSN) was reported by JP Morgan on March 19, 2024. The analyst firm set a price target for $5.00 expecting MRSN to rise to within 12 months (a possible 53.85% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Mersana Therapeutics (MRSN)?
The latest analyst rating for Mersana Therapeutics (NASDAQ: MRSN) was provided by JP Morgan, and Mersana Therapeutics upgraded their neutral rating.
When was the last upgrade for Mersana Therapeutics (MRSN)?
The last upgrade for Mersana Therapeutics Inc happened on March 19, 2024 when JP Morgan raised their price target to $5. JP Morgan previously had an underweight for Mersana Therapeutics Inc.
When was the last downgrade for Mersana Therapeutics (MRSN)?
The last downgrade for Mersana Therapeutics Inc happened on July 28, 2023 when Citigroup changed their price target from $10 to $1 for Mersana Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Mersana Therapeutics (MRSN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mersana Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mersana Therapeutics was filed on March 19, 2024 so you should expect the next rating to be made available sometime around March 19, 2025.
Is the Analyst Rating Mersana Therapeutics (MRSN) correct?
While ratings are subjective and will change, the latest Mersana Therapeutics (MRSN) rating was a upgraded with a price target of $0.00 to $5.00. The current price Mersana Therapeutics (MRSN) is trading at is $3.25, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.